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REVIEW
Neurovascular dysfunction in vascular 
dementia, Alzheimer’s and atherosclerosis
Osman Shabir1* , Jason Berwick1 and Sheila E. Francis2
Abstract 
Efficient blood supply to the brain is of paramount importance to its normal functioning and improper blood flow 
can result in potentially devastating neurological consequences. Cerebral blood flow in response to neural activity 
is intrinsically regulated by a complex interplay between various cell types within the brain in a relationship termed 
neurovascular coupling. The breakdown of neurovascular coupling is evident across a wide variety of both neuro-
logical and psychiatric disorders including Alzheimer’s disease. Atherosclerosis is a chronic syndrome affecting the 
integrity and function of major blood vessels including those that supply the brain, and it is therefore hypothesised 
that atherosclerosis impairs cerebral blood flow and neurovascular coupling leading to cerebrovascular dysfunction. 
This review will discuss the mechanisms of neurovascular coupling in health and disease and how atherosclerosis can 
potentially cause cerebrovascular dysfunction that may lead to cognitive decline as well as stroke. Understanding the 
mechanisms of neurovascular coupling in health and disease may enable us to develop potential therapies to prevent 
the breakdown of neurovascular coupling in the treatment of vascular brain diseases including vascular dementia, 
Alzheimer’s disease and stroke.
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Background
he human brain accounts for just 2% of total body 
weight, yet receives between 15 and 20% of total car-
diac output [1]. It is therefore evident that the brain 
requires an eicient and adequate blood supply to sup-
port the metabolic demands it exerts. Unlike the major-
ity of organs and tissues, the brain has a tightly regulated 
blood brain barrier (BBB), which prevents leakage of 
blood into the parenchyma and protects the brain from 
toxic agents and infection. Neurons, therefore, are not 
in direct association with the blood, but are function-
ally and structurally connected to a network of cell types 
within a structure called the neurovascular unit (NVU) 
[2]. he NVU facilitates cerebral blood low (CBF) 
changes in response to the metabolic activity of neu-
rons in a relationship termed neurovascular coupling [3]. 
Neurovascular coupling ensures that the brain has a pro-
portionally matched CBF in response to neural activity, 
however dysfunction of neurovascular coupling, either 
caused by pathology or ageing itself, can cause further 
cerebral pathologies and neurological disorders. his 
review will focus on the neurophysiology of neurovas-
cular coupling, how it is impaired in certain neurological 
conditions, how to study it and will discuss how cardio-
vascular disease may afect the regulation of CBF and 
neurovascular coupling.
Neurovascular coupling
The neurovascular unit and the blood brain barrier
he NVU consists of neurons, astrocytes, microglia, 
interneurons, pericytes, vascular smooth muscle cells 
(VSMCs) and endothelial cells [2]. It includes the difer-
ent cell types involved in the structural and functional 
connection between neurons and blood vessels in the 
brain, including cells involved in the formation of the 
BBB, refer to Fig.  1. he BBB is formed due to the spe-
cialised functions of tight-junctions of endothelial cells 
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in cerebral vasculature, astrocytes, with some evidence 
suggesting a crucial role for pericytes [4]. he BBB is a 
specialised structure in the cerebral vasculature, and is 
not seen in many other organs. It serves to limit the entry 
of pathogens, toxic agents and blood cells into the paren-
chyma [5], protecting the brain from infection, whilst 
allowing controlled transport of nutrients back and forth 
from the brain. However, there are natural pathogens that 
can penetrate the BBB including group B streptococci, 
which can cause meningitis [6]. Generic or specialised 
dysfunction of the NVU is associated with an increasing 
list of pathologies, including stroke, Parkinson’s disease, 
Alzheimer’s disease, multiple sclerosis, amyotrophic lat-
eral sclerosis and vascular dementia [2]. Speciic pathol-
ogies as a result of NVU and BBB dysfunction will be 
discussed later.
Neurophysiology of neurovascular coupling
he NVU facilitates haemodynamic changes (altera-
tion in CBF) in response to neural activity. his rela-
tionship is termed neurovascular coupling or functional 
hyperaemia, and is essential for normal metabolic func-
tioning of neurons and the brain as a whole [3], Fig.  2. 
Neurovascular coupling is thought to be governed by 
direct neural and endothelial interactions, or through 
complex neurogliovascular signalling pathways (of which 
some are highlighted in Fig. 2). Neural activation causes 
neurotransmitter release from synaptic terminals (e.g. 
glutamate), which bind to N-methyl-d-aspartate recep-
tors (NMDARs) or metabotropic glutamate receptors 
(mGlutRs) on nNOS-expressing interneurons initiates 
the synthesis of nitric oxide (NO) [7]. NO can directly 
cause vasodilation in the endothelium by stimulating 
cGMP in VSMCs. NO also inhibits CYP4A, which is 
needed to produce 20-HETE; a prominent vasoconstric-
tor [8].
Most neurons do not directly innervate the overall vas-
culature; rather glial intermediaries make the majority of 
neural-mediated inputs (refer to Fig. 1). With respect to 
neurogliovascular signalling, the most important players 
are thought to be astrocytes whose terminal processes 
called vascular end-feet, wrap around blood vessels in the 
brain to contribute to BBB integrity, as well as facilitating 
neurovascular coupling. Calcium, sodium and potassium 
signalling via the astrocytic-endothelial axis within the 
NVU may promote a slow and prolonged vasodilation 
Fig. 1 The neurovascular unit and the BBB at a capillary. Cerebral arteries have extensive vascular smooth muscle cell (VSMC) coverage regulating 
vasoconstriction. Capillaries on the other hand lack vascular smooth muscle cells, and are instead covered by small pericytes which maintain 
the integrity of the BBB, as well as regulate their diameter. Cerebral vessels receive inputs from astrocytes by their end-feet to regulate arteriolar 
diameter, as well as inputs from various interneuron groups
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compared to neural outputs, however this is contested 
by Lauritzen’s group who suggest that astrocytes are 
involved in the initial vasodilation [9]. On the other hand, 
rapidly induced transient vasodilation caused by neural 
NO [10], ensures that CBF change is suicient to match 
the demands of metabolic expenditure. Furthermore, it 
has been shown that a transient loss of oxygen and glu-
cose (as in ischaemia) causes excitotoxicity in neurons 
leading to delayed neuronal death [11]. At the centre of 
this excitotoxicity is a delayed mitophagy response (loss 
of mitochondria) from astrocyte end-feet, leading to a 
toxic increase in intracellular calcium  [Ca2+]IC and glu-
tamatergic activation [11], leading to neuronal death. 
Although functional neurovascular coupling is related to 
increased neural activity (i.e. stimulation of brain areas), 
the brain at rest also requires an eicient steady supply 
of blood low. Astrocytes have been shown to inluence 
arteriolar tone by a steady low-level elux of prostaglan-
din-E2  (PGE2) as a result of basal  [Ca
2+]IC luctuations 
in astrocytic end-feet [12]. his basal tonic inluence of 
arteriolar diameter is independent from stimulus-evoked 
neural activity-dependent haemodynamic changes, with-
out afecting stimulus-evoked functional hyperaemia. It 
is therefore assumed that astrocyte dysfunction is key to 
the breakdown of neurovascular coupling and therefore 
many neurological conditions.
In addition to astrocytes, interneurons also play a role 
in neurovascular coupling. Interneurons in the cortex 
come in distinct varieties: VIP/ChAT, NOS/NPY, SOM 
[7] as well as paravalbumin-GABAergic interneurons [13]. 
Depending on the input these interneurons receive, they 
have diferent outputs with respect to vasoconstriction or 
vasodilation. For example, acetylcholine (ACh) binding 
to muscarinic receptors on NOS-interneurons causes the 
release of NO to facilitate vasodilation on nearby micro 
vessels, however a serotonergic (5-HT) input on the same 
interneurons can cause the release of NPY, which can 
facilitate vasoconstriction [7]. he role of interneurons 
Fig. 2 Neurophysiology of neurovascular coupling overview. Neural activity is metabolically expensive demanding a high consumption of 
glucose and oxygen (from arterial blood). Simultaneously,  CO2 and other by products are also produced, which need to be removed by diffusion 
into venous blood in order to prevent hypercapnia and acidosis. In order to achieve this, neurons regulate blood flow via neurovascular coupling. 
Vasoactive agents such as NO directly cause vasodilation of arterial smooth muscle cells. Significant neurogliovascular signalling involving 
glutamate and calcium signalling causes vasodilation via channels on VSMCs e.g.  BKCa, TRPV4, to stimulate cGMP [105]. There are indeed multiple 
and complex signalling pathways (including ATP and VIP signalling) also involved in neurovascular coupling. In addition to vasodilator signals, 
vasoconstrictive signals are also produced, namely 20-HETE, however this is thought to be pathological and as a result of ageing [106]. Pericytes 
regulate capillary diameter by responding to glutamate release, in addition to  PGE2 produced by astrocytes
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in neurovascular coupling is still poorly understood and 
elucidating the mechanistic pathways involved is still to 
be fully investigated.
As arterioles turn into capillaries in the parenchyma, 
cerebral vessels no longer have a coverage of VSMCs and 
instead have a scattered covering of specialised contrac-
tile cells called pericytes [14]. Pericytes are an impor-
tant component of the BBB and maintain its integrity by 
regulating adherens junction proteins on endothelial cells 
[15]. he exact function and role of pericytes in the adult 
CNS is highly controversial. For example, Hall and col-
leagues published that pericytes are critically involved 
in the regulation of CBF [16] which was also supported 
by Kisler et  al. [17]. However, Hill et  al. [18] found that 
arteriolar smooth muscle cells; and not pericytes, regu-
late regional blood low. Furthermore, recent evidence 
has suggested that there may be several types of peri-
cytes with difering roles such as pre-capillary pericytes 
with smooth muscle actin (SMA), and capillary peri-
cytes without SMA expression [19–22]. Some evidence 
suggests that astrocytes may regulate pericyte tone and 
therefore vascular tone [22]. Although pericytes may be 
involved in capillary alterations, it is true that the arteries 
and arterioles, which are covered with VSMCs, need to 
be regulated to bring about a substantial change to CBF. 
It is evident from contradictions in the literature that 
regulation of CBF is not a simple mechanism (or as illus-
trated in Fig. 2); rather it is a complex interplay between 
various cell types and signalling pathways with many 
gaps still remaining in our understanding of the exact 
mechanisms behind neurovascular coupling in health 
and disease.
Neuroimaging techniques to study neurovascular coupling
In order to study and measure neurovascular coupling 
as well as structural alterations to the NVU in vivo, live 
neuroimaging techniques are used. Neuroimaging tech-
niques allow (largely) non-invasive visualisation of the 
brain, and are typically employed clinically to aid the 
diagnosis of disease, as well as in research to understand 
brain function physiologically and pathologically. Many 
of the clinical techniques can also be efectively used in 
pre-clinical imaging of animal models in vivo in studies of 
neurovascular coupling and cerebrovascular pathologies.
Functional magnetic resonance imaging (fMRI) has 
been the neuroimaging technique of choice for studying 
brain function in humans and to some extent in rodent 
models [23]. Briely, fMRI is based on nuclear magnetic 
resonance related to proton alignment with a magnetic 
ield [24]. he most commonly used detection paradigm 
is that of blood oxygen level dependent (BOLD) con-
trast. BOLD exploits the magnetic diferences between 
oxyhaemoglobin (HbO) and deoxyhaemoglobin (HbR). 
In a resting state, the relative ratio between HbO:HbR 
is equal, therefore the magnetic ield is unafected [25]. 
Upon neural activation and consequent increased CBF, 
the proportion of HbO increases relative to HbR there-
fore creating an inhomogeneity in the magnetic ield 
[25], which can be detected by a fMRI scanner. A posi-
tive BOLD signal generally relects increased neural 
activation, whereas a negative BOLD signal may relect 
decreased neural activity, and therefore blood low [26], 
although this relationship is not always truly relective of 
underlying neural activity especially in cases of pathology 
or speciic cell type activation. fMRI can be used in both 
human subjects for psychiatric/psychological studies of 
brain function, clinically in the diagnosis of neurological 
disease, as well as pre-clinically in animal models.
fMRI and related BOLD-based imaging techniques 
make inferences of neural activity by measuring corre-
sponding haemodynamic changes and do not measure 
neural activity directly. Neural activity can be recorded 
by directly measuring action potentials (spiking activity), 
or the summation of electrical activity determined by 
local ield potentials (LFPs). In order to measure the elec-
trical activity of neurons in vivo, multichannel microelec-
trodes are implanted in the brain region of interest, or on 
top of the scalp, producing electrical waveform data [27]. 
Correlating electrical neural activity to haemodynamic 
data enables direct association of neural events to corre-
sponding haemodynamics in the study of neurovascular 
coupling, and is important to do so as blood low may or 
may not be directly related to changes in neural activity.
To overcome some of the limitations of individual tech-
niques and to provide a comprehensive representation 
with respect to brain activity, a multimodal approach is 
typically used in the study of neurovascular coupling with 
the combination of two or more techniques. For example, 
2D-OIS (optical imaging spectroscopy) or BOLD-fMRI 
can be combined simultaneously with a micro-electrode 
implant for electrophysiology, or surface electroenceph-
alography (EEG) into give both a haemodynamic and 
neural response [26, 28]. For example, a recent study has 
shown that multiple sclerosis (MS) patients show reduc-
tions in gamma power (through magnetoencephalog-
raphy; MEG) as well as a reduction in BOLD (by fMRI) 
and CBF responses to visual stimulation [29]. It is impor-
tant to consider not only a BOLD (blood oxygen level 
dependent)-related haemodynamic response in neuro-
imaging, but the source of neural activity itself, as blood 
low changes often lag with respect to neural activity and 
may even decouple substantially in neurological disor-
ders such as Alzheimer’s disease (AD) [17, 30].
At rest, neurons typically have a low basal  [Ca2+] con-
centration of appropriately 50  nM, which is kept con-
stant due to the action of several calcium ion channels 
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and pumps such as the elux plasma membrane calcium 
ATP-ase (PMCA) [31]. Upon neural activation (propa-
gation of an action potential), inlux calcium channels 
such as voltage gated calcium channels (VGCCs) and 
glutamate-mediated NMDA receptors, allow a signii-
cant inlux of intracellular calcium with levels rising to 
100-fold higher than baseline [32]. herefore, neural 
activity directly correlates with changes to  [Ca2+] levels. 
hese indicators can be virally injected into the brain, 
or genetically engineered. Genetically encoded calcium 
indicators (GECIs) are bioluminescent protein complexes 
with integral luorophores, which when stimulated emit a 
resonance signal in the form of visible light which can be 
detected by a camera, allowing quantiication of neural 
activity based on the level of luminescence emitted by the 
luorophore. Examples of common GECIs include Yellow 
Cameleon 3.60 (YC3.60), which contains an enhanced 
cyan luorescent protein (ECFP) donor luorophore, 
bound to a Venus protein acceptor luorophore, linked by 
a calcium-binding domain, calmodulin [33]. More recent 
GECIs include modiications to the GCaMP family, such 
as GCaMP6, which is a class of single-luorophore GECI, 
where calcium binding causes a conformational change 
in the integral luorophore (EGFP) to increase its own 
intensity [34]. Speciic GECIs and other luorescent pro-
teins can be used to label speciic and multiple cell types 
of the neurovascular unit simultaneously. his can also 
be achieved by 2D-OIS by measuring GCaMP-labelled 
neuronal activity, whilst simultaneously measuring hae-
moglobin relectance changes, as done in Hillman’s group 
[35] amongst others.
2-photon microscopy is a technique in which a sin-
gle laser emits two infrared (low-energy) photons to a 
focused region to cause excitation in luorophores to a 
higher-energy state [36]. As the luorophores return to 
their resting ground state they emit a light signal which 
is detected by a scanner. Calcium labelling of neurons 
and glial cells allows quantiication of neural activity by 
measuring transient changes in spiking activity [32]. Flu-
orescent labelling of other cell types, including endothe-
lium allows simultaneous blood low measurements 
(RBC velocity), and therefore neurovascular coupling 
at the cellular level [37]. Multi-labelling in live animals 
eliminates the need to attach electrodes to the area of 
interest, therefore allowing neural and haemodynamic 
measurements to be taken by 2-photon microscopy over 
long periods of time. For example, it has been shown that 
amyloidosis (visualised by Methoxy-X04) around cerebral 
vasculature (visualised by TRITC-Dextran) disrupts the 
NVU function by a displacement of astrocytic-end-feet 
(visualised by Rhod-2 AM-loaded astrocytes,) by reduc-
ing overall CBF (determined by RBC velocity) in an AD 
mouse model [38]. Despite robust neural activity being 
present, the slow-down of CBF marks a decoupling of 
neurovascular coupling in AD.
Most stimulation paradigms in pre-clinical research 
involves the mechanical stimulation of either whiskers 
or fore/hind-paws to evoke a neural and haemodynamic 
response in the somatosensory cortex to study neuro-
vascular coupling. Optogenetics involves expressing 
light-responding proteins such as channelrhodopsin 2 
(ChR2), a blue-light sensitive protein which upon stim-
ulation causes labelled cells to become active [39]. Neu-
rons, as well as astrocytes, interneurons or even pericytes 
can be tagged with ChR2 in the cell-speciic optogenetic 
stimulation approach. Adapting the correct ilters in the 
2D-OIS setup can allow the simultaneous optogenetic 
stimulation by blue light whilst also measuring haemo-
dynamic changes as well as GECI-labelled neurons, in a 
shift to an all-optical approach to studying neurovascular 
coupling in vivo.
Neurovascular dysfunction in neurological disorders
Many neurological conditions including the common 
neurodegenerative disorders display some level of neu-
rovascular dysfunction; which either initiates or contrib-
utes to their pathogenesis, or is caused as a consequence. 
he neurovascular dysfunction seen in disorders such as 
Alzheimer’s and stroke can be directly attributed to car-
diovascular deicits, however in some cases it may also 
not be directly associated with any underlying cardio-
vascular pathology, rather a functional breakdown of the 
neurovascular unit and signalling pathways.
Dementia (Alzheimer’s disease)
For the irst time since medical records began, dementia 
has become the single-most leading cause of death in the 
UK surpassing heart disease, strokes and major cancers 
[40]. With an ever-ageing population, higher life expec-
tancy and advances in diagnosis techniques, dementia 
currently afects as many as 1 in 6 in the UK [40]. Of the 
dementias, AD is the most prevalent followed by vascu-
lar dementia, whereas the remainder of cases comprise 
of frontotemporal dementia (FTD), dementia with Lewy 
bodies (DLBs) and early-onset dementia. In most of these 
cases, a mild cognitive impairment stage usually occurs 
much earlier on before the onset of dementia.
AD is an age-related neurodegenerative disorder and 
the most frequent form of dementia worldwide [41]. he 
primary pathological hallmarks of AD consist of extra-
cellular β-amyloid (Aβ) plaques and intracellular neu-
roibrillary tangles (NFTs) of hyper-phosphorylated tau 
[42]. Familial cases of AD arise in an autosomal dominant 
inheritance pattern due to mutations to either amyloid 
precursor protein (APP), presenilin 1 (PSEN1) and prese-
nilin 2 (PSEN2) [43–45]. Familial AD is usually relatively 
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early-onset, however only accounts for around 10% of all 
AD cases worldwide [46]. Although genetic mutations in 
AD account for a small proportion of all AD cases, most 
of our understanding of AD pathology and mechanisms 
have come from animal models with these genetic muta-
tions, for example the J20 mouse (PDGFB-hAPPSwInd) 
harbours the more common APP mutation called the 
Swedish K670 N/M671L mutation as well as the Indiana 
V717F mutation, which both increase β-secretase activ-
ity [47, 48]. he increased production of the toxic form 
of amyloid, Aβ42, as well as Aβ40, coupled with the 
decreased ability to clear aggregates is the primary cause 
of Aβ-plaque build-up in the pathogenesis of AD [49]. 
Figure 3 illustrates the amyloidgenic processing pathway 
in the formation of Aβ plaques.
he vast majority of AD cases are sporadic (~ 90%) and 
are relatively later-onset, and are therefore not attribut-
able to inherited genetic mutations to amyloid processing 
genes. It is important to note that even in sporadic AD 
cases, β-amyloid plaques are still present, and has many 
similarities to familial AD. Amongst the common risk 
factors already associated with cardiovascular disease 
and dementia such as age, hypertension, hypercholester-
olaemia, diabetes etc., there are several risk factor gene 
polymorphisms which greatly enhance the likelihood of 
developing AD. he most common is the APOEε4 allele 
which is attributed to up to approximately 50-60% of all 
AD cases [50] as carrying the allele (found in around 15% 
of the population) increases the risk of developing AD 
fourfold, and homozygous inheritance of the APOEε4 
increases the risk ninefold [50]. APOEε4 AD-patients 
have amyloid-β plaques as well as phosphorylated-tau 
NFTs similar to familial AD [51, 52]. he knowledge 
gained from the use of genetic models of AD therefore 
also applies to a vast proportion of all AD cases where 
amyloid is present.
here is a growing body of evidence which suggests 
that neurovascular coupling may be impaired in AD 
[21, 30, 53, 54]. It is postulated that impaired blood low 
responses to neural activity as a result of neurovascular 
disarray may cause a mismatch between neural activity 
and provision of oxygen and glucose to meet suiciently 
adequate metabolic demands. Consequentially, neural 
activity is reduced and thus correlates with impaired cer-
ebral function, manifested clinically as cognitive decline 
[30]. As discussed previously, pericytes are critical in the 
integrity and maintenance of the BBB and therefore the 
NVU. Recent evidence has shown that patients with AD 
Fig. 3 Overview of Aβ processing. APP can be processed via the α-secretase pathways (non-amyloidgenic pathway) producing the soluble APPs-α 
fragment and a small p3 fragment. The amyloidgenic pathway utilises β-secretase to produce the soluble APPs-β fragment followed by γ-secretase 
producing Aβ40 or lower in a much higher ratio than the production of Aβ42. Mutations to PSEN1/2 and APP (such as the Swedish mutation, 
marked by a red star on APP) often favour the production of the more toxic Aβ42 fragment which forms oligomers leading to the formation of 
Aβ-plaques. Adapted from [51, 70]
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carrying the APOEε4-allele have a BBB breakdown attrib-
uted to pericyte degeneration in which patients/carriers 
have up to 50% less pericyte coverage correlating with 
almost 300-400 mm/mm3 total capillary length reduction 
compared to control subjects without the APOEε4 allele 
[55]. his study is further supported by Kisler et al. [17] 
in which they found that  PDGFRB−/− (pericyte deicient) 
mice have a reduced cerebral oxygenation level compared 
to controls as well as neurovascular uncoupling leading 
to neuronal death [17]. More recent evidence has directly 
implicated pericyte degeneration in extensive white mat-
ter pathology characterised by hypoxia and loss of mye-
lination, leading to the loss of structural and functional 
connections within the brain which are typically present 
in some AD cases [56]. he breakdown of the NVU (peri-
cytes amongst other cell types within the NVU) and the 
BBB is evident in Alzheimer’s patients, and may con-
tribute to exacerbated pathology seen in AD, as well as 
initiating neuropathology. his can be further explained 
in the 2-hit vascular hypothesis model of AD proposed 
by Zlokovic [57] (Fig. 5). he irst ‘hit’ refers to vascular 
dysfunction caused by various risk factors including ath-
erosclerosis leading to a breakdown of vascular integrity 
causing reduced CBF which in itself can cause stroke 
(discussed below), cognitive decline and vascular demen-
tia. he second ‘hit’ refers to the increased Aβ levels (by 
a reduction in clearance) which further exacerbates neu-
ronal dysfunction and adding further insult to the patho-
genesis of AD [57]. It is therefore becoming increasingly 
more apparent that AD is not solely a neurodegenerative 
disorder, rather it is a complex multifactorial disease with 
a large neurovascular element which needs to be investi-
gated further both in disease initiation and in potential 
therapeutic strategies.
Stroke
Vascular dementia and other forms of cognitive impair-
ment can be caused directly by having a stroke. Strokes 
can arise as a direct consequence of arterial pathology 
with profound changes to the neurovascular unit and 
the normal physiology of neurovascular coupling. his 
impaired blood low to the brain can lead to the death of 
neural tissue in speciic regions where blood low is dis-
rupted to cause a stroke. Depending on the severity of the 
stroke, symptoms can be mild ranging from a transient 
ischaemic attack to a potentially fatal in a stroke where a 
large are of the brain is afected [58]. Strokes can fall into 
two broad categories: ischaemic, where occlusion of ves-
sels leads to death of tissue; or haemorrhagic as a result 
of a ruptured vessel [58]. As a consequence of stroke, 
cognitive and motor function can become impaired, 
sometimes permanently leading to vascular dementia for 
example.
Subarachnoid haemorrhages (SAH) as a result of cer-
ebral aneurysm rupture can cause a devastating stroke 
which usually results in death a few days after the initial 
rupture, if not fatal during the initial stroke [59]. It has 
been demonstrated that in such haemorrhagic episodes, 
there tends to be an inversion of neurovascular coupling 
in response to calcium-signalling mediated by astrocytes 
[59]. Instead of  Ca2+-mediated vasodilation, post-stroke, 
there is a switch in the polarity of neurovascular coupling 
in which  Ca2+ actually causes vasoconstriction patho-
logically. his then limits CBF and functional hyperae-
mia to the brain parenchyma resulting in progressive 
ischaemia after the stroke takes place usually resulting 
in death of the patient a few days after the stroke [59]. 
A potential mechanism as to why this may occur may 
be due to the upregulation of astrocytic endothelin-1 
(ET-1); a vasoconstrictor, after SAH [60]. ET-1 binds to 
 ETB1 receptors on endothelial cells to reduce overall syn-
thesis of endothelial nitric oxide synthase (eNOS), and 
hence NO levels. ET-1 also binds to  ETA receptors on 
the tunica media of vessels to upregulate PKC-α, which 
in turn inhibits the function of  K+ channels to contrib-
ute to vasospasm, and BBB breakdown causing oedema 
[60]. hese studies highlight the importance of astrocytes 
in neurovascular coupling by alluding to the critical sig-
nalling pathways between neurons-astrocytes-endothe-
lial cells in facilitating vasodilation, as well as providing 
insight into the complexity of stroke pathophysiology.
Physiological ageing
Ageing is itself the biggest risk factor in the development 
of many diseases including cardiovascular disease, Alz-
heimer’s and vascular dementia. Normal physiological 
ageing itself results in progressive neurovascular dysfunc-
tion, primarily marked by a reduction of overall CBF [61, 
62]. A key reason why many age-related disorders begin 
is due to the accumulation of reactive-oxygen species 
(ROS) coupled with impaired ROS-scavenging. Indeed, 
it has been shown that an enhanced production of ROS 
leads to an overall reduction in NO within the vascula-
ture, therefore impacting NO signalling to cause vaso-
constriction over time [10]. his arises as a direct result 
of aged vessels afecting their structure and function.
A recent study by Duncombe and colleagues explored 
the pathophysiology of neurovascular coupling associ-
ated with ageing [63]. hey found that aged mice show 
key diferences in the NVU compared to younger mice. 
Firstly, pericyte coverage is markedly reduced in older 
mice [63]. However, this study did not ind any correla-
tive efects of the loss of pericytes with CBF and altera-
tions to neurovascular coupling. his is contradicted by 
another study by Kisler and colleagues [17], which found 
that the loss of pericytes directly causes neurovascular 
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uncoupling, in addition to reduced oxygen perfusion in 
the brain [21]. As alluded to earlier, studying the role of 
pericytes in neurovascular coupling is a challenging task, 
mainly as there are few speciic markers for pericytes, as 
well as limited scope to study blood low in capillaries 
in vivo, which is acknowledged by Duncombe. Secondly, 
Duncombe and colleagues found that aged mice exhibit 
astrocyte end-feet abnormalities by the marked reduction 
in the expression of AQP4 [63], which impairs the cell–
cell communication between astrocytes and endothelial 
cells via the neurogliovascular signalling pathways (as 
shown in Fig. 2). Ageing, therefore, progressively impairs 
functional hyperaemia by a wide variety of pathophysi-
ological changes associated with the NVU, in addition to 
the loss of key signalling pathways, which may be further 
worsened in AD through excitotoxic calcium signalling 
due to Aβ plaque pathology [64].
Atherosclerosis
One key pathological change associated with ageing 
is that of atherosclerosis. Atherosclerosis is a chronic 
inlammatory syndrome resulting in the progressive 
thickening and hardening (arteriosclerosis) of major 
artery walls [65]. his continual narrowing of the lumen 
restricts blood low over time, and is causative in mil-
lions of deaths worldwide each year with the commonest 
causes of death being stroke, myocardial infarction and 
dementia [66]. he aetiology of atherosclerosis is com-
plex with a combination of genetic, lifestyle (e.g. dietary), 
environmental and immunological factors contributing 
towards its pathogenesis and progression.
Atherosclerosis can take decades to take full efect with 
patients being largely asymptomatic until their mid-50 s, 
although initiation of disease takes place in early adult-
hood. he initiation of atherosclerosis is still not fully 
understood, although general consensus is that athero-
sclerosis begins with inlammatory changes within the 
endothelium caused by low-density lipoproteins (LDLs) 
being deposited [67, 68], and internalised by endothelial 
cells. However, what is becoming increasingly clearer is 
that deposition of LDLs into the arterial walls is not suf-
icient to cause atherogenesis, rather it is the subsequent 
immune response facilitated by monocytes and leuko-
cytes that initiates the syndrome [69], Fig. 3.
LDLs have been shown to deposit more readily in ath-
erosclerotic-prone and low blood low areas of an arte-
rial branch, where they undergo oxidation by reactive 
oxygen species (ROS), stimulating an immune-response 
[70]. he arterial branches susceptible to LDL deposi-
tion and atherosclerosis tend to be near areas of major 
curvatures (e.g. carotid sinus) which have a high shear 
index compared to laminar areas of the same arterial 
tree, that tend to be more athero-reistant [71].
he solidifying step in atherogenesis is when invading 
monocytes diferentiate into macrophages in the intima 
after binding to endothelial receptors such as VCAM1 
and P-Selectin [72], Fig. 4. Once diferentiated into mac-
rophages, oxidised-LDLs are subsequently engulfed, 
slowly transforming normal macrophages into ‘foam-
cells’ with a large accumulation of lipids intracellularly 
[73]. Over time, clusters of foam cells form visible ‘fatty-
streaks’ inside the intima of the endothelium. Simultane-
ous to fatty-streak formation, endothelial VSMCs also 
begin to proliferate and migrate from the media into the 
intima and form a ring around the fatty-streaks further 
stabilising the forming plaque [74]. Over time some of 
the VSMCs begin to calcify and harden adjacent to the 
atheromatous endothelium, forming a solid core in the 
intima of the endothelium, which begins to enlarge and 
partially occlude the vessel to cause a progressive nar-
rowing (stenosis) of the artery [75].
he atheromatous plaque (atheroma) may in itself 
cause an obstruction of blood low, or more commonly 
the atheroma may rupture and form a thrombus with 
platelets, which can be repeated to form a stable cap dis-
rupting blood low over time further exacerbating steno-
sis, or rupturing within the vessel wall to cause either an 
embolism or haemorrhage. Either of these can contribute 
to coronary heart disease, myocardial infarction (if in the 
heart), or a stroke if in the carotid or cerebral arteries.
Atherosclerosis and neurovascular dysfunction
Atherosclerosis afects most large to medium sized sys-
temic arteries including those supplying the cerebral 
circulation, namely the internal carotid and vertebral 
arteries [58]. Progressive plaque build-up and stenosis of 
cranial arteries can cause strokes as well as contribute to 
the development of dementia either directly or as a con-
sequence of stroke. Strokes can either be ischaemic or 
haemorrhagic in nature, and can both trace their origins 
to underlying vascular pathologies, such as luminal ste-
nosis as a consequence of atherosclerosis in the arteries 
supplying the brain and cranium [58]. Here, only the rela-
tionship between cardiovascular disease and cognitive 
impairment will be discussed.
Atherosclerosis and related cardiovascular diseases and 
risk factors can cause a wide array of simple and com-
plex vascular lesions in the brain. For example, bilateral 
carotid occlusion directly afects the blood supply to the 
brain, and is commonly associated with stroke and vascu-
lar dementia [76]. Some of the key vascular lesions com-
monly found in patients with cardiovascular pathology 
range from microbleeds, microinfarcts (lacunar multi-
infarct or strategic) and lipohyalinosis; the deposition 
of hyaline in the connective tissue walls to disrupt the 
integrity of the vasculature, afecting the smaller vessels 
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within the white matter termed cerebral small vessel 
disease [77], refer to Fig.  5. hese lesions arise directly 
as a consequence of arterial stifness and inlamma-
tion caused by atherosclerosis and vascular risk factors 
including hypertension, hypercholesterolaemia, smoking, 
diet and advanced age [78]. Cerebral small vessel disease 
is directly associated with the onset of dementia, primar-
ily vascular dementia as well as Alzheimer’s-like pathol-
ogy and other milder forms of cognitive impairment as 
well as stroke. Depending on where in the brain these 
vascular lesions occur, diferent symptoms may manifest 
clinically. Pre-symptomatic (subclinical) carotid athero-
sclerosis (determined by increased endothelial swelling 
Fig.  5) is associated with early cognitive impairment, in 
which pathologic mechanisms have been attributed to 
cerebral microvascular dysfunction (as shown in Fig.  5) 
in the frontal and temporal lobes [79].
Lipohyalinosis is a brain-speciic vessel disease char-
acterised by vascular wall disruption and occurs as a 
result of systemic atherosclerosis, especially due to 
extensive inlammation occurring through the accumu-
lation of ROS, in addition to gliosis involving astrocytes, 
oligodendrocyte precursor cells and microglia which 
themselves in their reactive state produce ROS [80]. As 
discussed previously, atherosclerosis is an inlamma-
tory syndrome which initiates as a result of an immune 
response against oxidised-LDLs in the intima. Mono-
cyte iniltration into the vessel wall followed by diferen-
tiation into macrophages which subsequently engulf the 
oxidised-LDLs forming foam cells is the primary inlam-
matory trigger [69]. In addition to monocyte iniltration 
at sites of LDL retention,  TH1  (CD4
+) lymphocytes are 
also involved in the inlammatory response [72, 81].  TH1 
cells bind to antigen sites on LDL molecules and sub-
sequently produce inlammatory mediators including 
tumour necrosis factor (TNF) and interferons e.g. IFNγ 
[72], which all promote the pathogenesis and develop-
ment of atherosclerosis. Cholesterol crystals activate the 
NOD-like receptor protein 3 (NLRP3), which together 
with caspase-1 and apoptosis-associated speck-like pro-
tein containing a caspase activation and recruitment 
domain (CARD) forms an inlammasome [82]. his 
stimulates the production of the proinlammatory IL-1β 
chemokine. IL-1β has been shown to be implicated in 
Fig. 4 Overview of the pathogenesis of atherosclerosis. Accumulation of LDLs in the blood leads to LDLs being transported into the endothelium, 
where they become oxidised. Infiltrating monocytes become activated and differentiate into macrophages and begin to ingest oxidised-LDLs to 
become foam cells. Over time, foam cells conglomerate to form fatty streaks. Simultaneously, due to inflammation and stimulant factors, VSMCs 
begin to proliferate and migrate into the intima and form a cap around the fatty streak. Endothelial cells overlying the growing plaque become 
calcified, with reduced elasticity. Over time this cap restricts blood flow due to a luminal constriction. If the plaque ruptures, a thrombus forms and 
obstructs the lumen completely, or partially. This can lead to ischaemia downstream leading to an ischaemic attack in the brain, or rupture to cause 
a haemorrhagic stroke. Adapted from [107]
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the pathogenesis of atherosclerosis and thrombosis by 
the downstream stimulation of IL-6 and C-reactive pro-
tein (CRP) [83]. Recent evidence has suggested that tar-
geting the inlammatory pathways in atherosclerosis 
irrespective of reducing LDL-C levels, may actually be 
therapeutically beneicial in patients with atheroscle-
rosis, by reducing the frequency and strength of major 
cardiovascular incidents [83, 84]. Clinical trials involving 
canakinumab, a monoclonal antibody against IL-1β, has 
shown a signiicant reduction of major cardiovascular 
incidents in patients with atherosclerosis, by reducing the 
total levels of plasma IL-6 and CRP compared to those 
given a placebo [83].
Fig. 5 Vascular lesions in small vessel disease. Key types of vascular lesions found in the brain as a result of small vessel disease (SVD) leading 
to cognitive impairment (vascular dementia) and stroke include microbleeds, microinfarcts; where fatty deposits accumulate to restrict luminal 
diameter, and inflammatory white matter pathology such as lipohyalinosis, where hyaline deposits within connective tissue in addition to astrocytic 
gliosis (scarring) and wall swelling to disrupt the uniformity of vessel walls within the brain. Adapted from [76]
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Vascular dysfunction caused by atherosclerosis and 
lifestyle/genetic risk factors can directly lead to cer-
ebral vascular damage to cause small vessel disease and 
a breakdown of the BBB, marked by inlammation and 
hyper-connectivity [21]. his vascular damage leads to 
neurovascular dysfunction marked by CBF decrease 
(oligemia), as well as potentially initiating Aβ pathology 
by a reduction in clearance. Figure 6 illustrates how AD 
can develop (including the 2-hit vascular model pro-
posed by Zlokovic [57]) as a result of vascular dysfunc-
tion leading to amyloid production, in addition to the 
pathogenesis of vascular dementia at the level of neuro-
vascular dysfunction, independent of amyloid pathol-
ogy. Figure 6 also summarises the key processes involved 
in atherogenesis and vascular dysfunction, including 
inlammation, showing the complex overlap between dis-
ease conditions.
LDLR, ApoE and PCSK9
LDL molecules comprise of an apolipoprotein B-100 pro-
tein, in addition to other lipids (including up to 1500 cho-
lesterol molecules), triglycerides and structural protein 
complexes [85]. LDLs bind to the LDL-receptors (LDLRs) 
in hepatocytes, primarily, via the ApoB segment to stim-
ulate endocytosis of the LDLR/LDL complex [86]. he 
closely related ApoE protein, which also binds to LDLR, 
is involved in the selective transport of lipoproteins sys-
temically, especially in the transport of chylomicron and 
LDL remnants [87]. Genetic mutations that cause a loss 
of function to either the LDLR, ApoE or ApoB of an LDL 
molecule result in the reduced clearance of LDL from the 
plasma, therefore increasing the circulating plasma levels 
of cholesterol [88]. Whilst mutations to these genes may 
cause familial hypercholesterolemia from a much earlier 
age, afecting as many people as around 1:500 (heterozy-
gotic) [88], non-afected individuals can naturally develop 
hypercholesterolemia and therefore atherosclerosis with 
elevated LDL levels either through dietary intake of trans 
and saturated fats, being obese, in addition to having dia-
betes, or simply being male [88].  ApoE−/− and  LDLR−/− 
knockout mice can develop hypercholesterolemia and 
atherosclerosis and disease severity and progression is 
exacerbated by being fed a high-fat diet [89, 90].  ApoE−/− 
mice also develop BBB leakage which worsens over time, 
and may contribute to a breakdown of neurovascular 
coupling [91, 92].
More recently, an rAAV8 D377Y-mPCSK9  (PCSK9DY) 
mouse model (on a male C57BL/6 background) has been 
used to study atherosclerosis [93–95], where a single 
injection of AAV-mPCSK9DY is suicient to cause long-
term atherosclerosis in mice comparable to  LDLR−/− 
strains, without the need to create a transgenic mutant 
knock-in line [93]. he proprotein convertase subtilisin/
kexin type 9 (PCSK9) gene on chromosome 1 (1p32.3) has 
been shown to homeostatically regulate cholesterol levels 
in the plasma by directly interacting with the LDL-recep-
tor (LDLR) and the related APOE-receptor  (ApoER2) by 
causing their internalisation and degradation within a 
cell [96, 97]. Over-time, the degradation of LDLR with 
respective increased plasma cholesterol levels may be 
Fig. 6 Summary of vascular pathologies in CVD, stroke and dementia. Vascular dysfunction pathway for stroke, vascular dementia and AD; 
AD-specific factors in red text (incorporating the 2-hit hypothesis for AD—hit 1 being at vessel damage and hit-2 being Aβ increase). CVD can 
directly cause cerebral vessel damage to cause either strokes and/or vascular dementia, in addition to initiating AD pathology if certain risk factors 
are present. Adapted from [21, 108]
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causative to atherosclerosis in ordinary individuals [98]. 
Gain of function mutations to PCSK9 (e.g. D374Y) are 
associated with patients that have genetic hypercholes-
terolemia, in particular, familial autosomal dominant 
hypercholesterolemia (FADHC) [99]. In the case of the 
human  PCSK9D374Y mutation, plasma concentrations of 
cholesterol can exceed 500  mg/dL, where normal levels 
would be less than 200  mg/dL and pathological being 
above 250  mg/dL [99]. Recently it has been shown that 
there is signiicantly increased PCSK9 within the CSF of 
Alzheimer’s patients carrying the APOEε4 allele, with a 
yet unknown pathway [100], further adding support to 
the notion that hypercholesterolaemia is a major risk fac-
tor for AD. With the knowledge that PCSK9 is involved 
in elevated cholesterol levels both physiologically and 
pathologically, monoclonal antibodies and selective 
inhibitors, such as alirocumab (against PCSK9), have 
been approved by the FDA for the treatment of patients 
with hypercholesterolemia and atherosclerosis by halting 
the progression of cardiovascular disease [101]. Figure 7 
illustrates the physiological and pathological mecha-
nisms of PCSK9 in the regulation of plasma cholesterol 
levels. It has been shown that a high-fat diet exacerbates 
atherogenesis by elevating total cholesterol levels in 
 PCSK9DY mice, much like the  LDLR−/− strains, however 
normal rodent chow can also result in moderate athero-
genesis [95]. As this is a relatively novel atherosclerosis 
model, not much is known about the efect on the brain 
or neurovascular coupling. his viral injection method 
of inducing atherosclerosis in any strain of mouse is far 
cheaper than breeding and maintaining inbred colonies, 
and it is becoming the model of choice due to its rapid 
induction (including in any genetic-model), reliable and 
consistent atherosclerotic proiles as well as cost. Com-
pared to the artiicially high serum cholesterol levels seen 
in the  ApoE−/− mice, and having the added beneit of not 
maintaining knockout lines, the rAAV-PCSK9DY model is 
certainly the more economical and more efective model 
in terms of induction of atherosclerosis as well as a com-
parable LDL-C proile to that of patients.
It is important to note that all animal models of human 
disease can never completely replicate human disease 
in  vivo, due to species-speciic physiologies; therefore, 
the models that we do have are our best insight into a 
more complex scenario with respect to human disease, 
and results must be interpreted with some level of cau-
tion before generalising both in terms of knowledge 
gained and potential for therapeutics. Although animal 
models can model human disease and provide insights 
into disease mechanisms efectively, sometimes the same 
model may provide conlicting evidence in the hands 
of other researchers. Studies have found a link between 
hypercholesterolemia and the onset of vascular dysfunc-
tion causing Alzheimer’s(-like) pathology in patients 
[102], as well as in high-fat diet mouse models [103]. 
However, in a study by Hohsield and colleagues [104], it 
was shown that hypercholesterolemia does not increase 
amyloid-deposition and Alzheimer’s like pathology in the 
same 3xTg-AD mouse model. However, unlike in the pre-
vious studies, the 3xTg-AD mice in Hohsield’s study did 
not survive long enough, therefore probably did not gain 
enough cumulative amyloid/tau deposition to manifest as 
Alzheimer’s-like pathology. hey did not consider more 
regular behavioural assays such as Morris maze tests to 
establish whether their mice displayed any early mild 
cognitive deicits.
Conclusion
Neurovascular coupling is critical to the proper func-
tioning of the brain, ensuring that increased neu-
ral activity, which itself is incredibly metabolically 
demanding, is matched with an appropriate change to 
Fig. 7 PCSK9 mechanisms. LDL low-density lipoprotein, LDL-C cholesterol, LDLR low-density lipoprotein receptor, PCSK9 proprotein convertase 
subtilisin/kexin type 9, HC hypercholesterolemia, g.o.f. gain of function, FADHC familial autosomal dominant hypercholesterolemia. a (Left)—
physiological homeostatic regulation of LDL-C by LDLR. a (Right)—physiological homeostatic regulation of LDLR by PCSK9 (which may lead to HC). 
b Genetic mutant (g.o.f.) variant of PCSK9 causing FADHC. c PCSK9 inhibitor mechanism to reduce LDL-C levels in patients with HC
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CBF to both nourish the parenchyma with oxygen and 
glucose as well as the quick and eicient removal of 
carbon dioxide and waste products. In order to achieve 
this, neurons communicate with endothelial cells via 
the neurogliovascular signalling pathways within the 
NVU. Pathological changes to the NVU and endothe-
lia impairs the signalling pathways involved in neuro-
vascular coupling, leading to brain pathologies ranging 
from subtle cognitive deicits to severe AD. Although 
our knowledge and understanding of the mechanisms 
behind neurovascular coupling in health, ageing and 
disease has vastly improved in recent years, much is still 
to be investigated, especially with respect to the efect 
of atherosclerosis on cerebral vasculature and neuro-
vascular coupling. Although there are many established 
models of atherosclerosis, the new rAAV-PCSK9DY 
method has many beneits over the conventional 
knock-out lines of  ApoE−/− and  LDLR−/−, including the 
ability to induce atherosclerosis in any mouse model 
including AD-mouse models. In future studies, track-
ing haemodynamic changes over time combined with 
cellular, genetic and in  vivo imaging would provide a 
comprehensive overview and mechanistic insight into 
how cardiovascular disease afects neurovascular cou-
pling and the brain as a whole in mouse models of ath-
erosclerosis and mixed models of dementia.
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